Viatris (VTRS) Gains Japan WAKIX Approval As Fair Value Still Sits Higher
Viatris (VTRS) just picked up a fresh regulatory win in Japan, where the country’s health ministry approved WAKIX for excessive daytime sleepiness linked to obstructive sleep apnea and narcolepsy, expanding the drug’s reach.
Viatris has been in the spotlight for more than just WAKIX, with a series of product updates and pipeline milestones landing over recent months while the share price has climbed to US$16.95 and logged a year-to-date share price return of 36.04% and a 1-year total shareholder return of 77.28%, pointing to momentum that has carried through the past quarter rather than fading.
Scan beyond Viatris and this WAKIX milestone. Size up other healthcare businesses with solid fundamentals using our curated list of solid balance sheet and fundamentals (23 results) as a comparison set.
After a run to US$16.95 backed by fresh WAKIX momentum, the real fork in the road now is simple. Do you put money to work in Viatris today, or wait for a cheaper shot at it?
Most Popular Narrative: 8% Undervalued
On the most followed narrative, Viatris is priced below an estimated fair value of $18.50, while the last close sits at $16.95. This puts fresh WAKIX news into a wider earnings and revenue story.
The company is well-positioned to benefit from sustained demand growth due to global population aging and increasing chronic disease prevalence, as demonstrated by positive late-stage pipeline developments in chronic disease, pain, and ophthalmology. This may set the stage for long-term revenue growth through new branded and generic launches in large, underserved markets.
See why 45 investors see Viatris as 8% undervalued.
Result: Fair Value of $18.50 (UNDERVALUED)
Still, that 8% discount argument can unravel quickly if price pressure on mature generics is stronger than expected or if ongoing integration and facility remediation costs continue to drag on profitability.
Find out about the key risks to this Viatris narrative.
Next Steps
Plenty of investors see a mixed picture here, with both pressure points and bright spots around Viatris. If you want to move quickly and base your stance on the underlying numbers rather than the headline narrative alone, start with the 3 key rewards and 1 important warning sign.
Looking for more Viatris sized investment ideas?
Do not stop with Viatris. Use the Simply Wall Street Screener to surface fresh company ideas that match your style before the next move gets crowded.
- Target potential mispricing by focusing on stronger fundamentals paired with attractive valuations through the 33 high quality undervalued stocks.
- Strengthen your income game by comparing high-yield candidates uncovered via the 6 dividend fortresses.
- Dial back risk while staying invested by filtering for sturdier balance sheets using the 30 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com